Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EPS (Basic) (2016 - 2025)

BioCorRx (BICX) has disclosed EPS (Basic) for 16 consecutive years, with -$0.02 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 83.6% to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.16 through Dec 2025, up 69.67% year-over-year, with the annual reading at -$0.14 for FY2025, 70.64% up from the prior year.
  • EPS (Basic) hit -$0.02 in Q4 2025 for BioCorRx, down from -$0.0 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.0 in Q3 2025 to a low of -$0.26 in Q1 2021.
  • Historically, EPS (Basic) has averaged -$0.13 across 5 years, with a median of -$0.13 in 2022.
  • Biggest five-year swings in EPS (Basic): crashed 50.0% in 2021 and later skyrocketed 99.9% in 2025.
  • Year by year, EPS (Basic) stood at -$0.19 in 2021, then grew by 15.51% to -$0.16 in 2022, then grew by 27.66% to -$0.12 in 2023, then decreased by 1.02% to -$0.12 in 2024, then soared by 83.6% to -$0.02 in 2025.
  • Business Quant data shows EPS (Basic) for BICX at -$0.02 in Q4 2025, -$0.0 in Q3 2025, and -$0.09 in Q2 2025.